Stockreport

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

IN8bio, Inc.  (INAB) 
PDF NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies [Read more]